United Therapeutics Corporation
UTHR
|
$237.06
1.11%
1.09%
610K
|
Health Technology
(0.0% 1d) (-4.4% 1m) (4.9% 1y) (0.0% 2d) (0.9% 3d) (-0.4% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-21
Market Cap: $ 11,155,698,678
http://www.unither.com
Sec Filling | Patents | 920 employees
(United States) United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
hypertension msa
Drugs
ADCIRCA (Tadalafil)Orenitram (treprostinil)
Remodulin (treprostinil)
Sterile Diluent for Remodulin (water)
Unituxin (DINUTUXIMAB)
add to watch list Paper trade email alert is off
Press-releases
United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
UTHR | $237.06 1.11% 1.09% 610K
|
Health Technology
|
| O: -0.56%
H: 3.16%
C: 1.45%
first therapeutics
United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024
Published: 2024-04-24 (Crawled : 12:00) - biospace.com/
UTHR | $237.06 1.11% 1.09% 610K
|
Health Technology
|
| O: -0.56%
H: 3.16%
C: 1.45%
first report corporation therapeutics financial results market
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
UTHR | $237.06 1.11% 1.09% 610K
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: -1.0%
conference international commercial therapeutics
United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation
Published: 2024-03-26 (Crawled : 12:30) - biospace.com/
UTHR | $237.06 1.11% 1.09% 610K
|
Health Technology
|
| O: 0.17%
H: 2.54%
C: 1.3%
first review publication therapeutics
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-03-13 (Crawled : 10:00) - globenewswire.com
UTHR | $237.06 1.11% 1.09% 610K
|
Health Technology
|
| O: 0.65%
H: 0.23%
C: -2.9%
LQDA S | $12.55 -3.09% -3.19% 1.1M
|
Health Technology
|
| O: 0.64%
H: 5.54%
C: 4.69%
year corporation update financial results
United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024
Published: 2024-03-05 (Crawled : 12:30) - biospace.com/
UTHR | $237.06 1.11% 1.09% 610K
|
Health Technology
|
| O: -0.19%
H: 1.76%
C: 0.66%
conference corporation biopharma global therapeutics
United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference
Published: 2024-02-27 (Crawled : 12:00) - biospace.com/
UTHR | $237.06 1.11% 1.09% 610K
|
Health Technology
|
| O: 0.15%
H: 2.13%
C: 1.27%
conference health corporation care therapeutics
Neuroblastoma Drugs Market to Reach $1.3 Billion, Globally, by 2032 at 6.2% CAGR: Allied Market Research
Published: 2024-02-26 (Crawled : 15:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: 3.06%
H: 0.0%
C: -2.34%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.23%
H: 1.16%
C: 0.08%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.19%
H: 0.23%
C: -2.02%
UTHR | $237.06 1.11% 1.09% 610K
|
Health Technology
|
| O: -0.48%
H: 1.17%
C: -1.04%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 0.38%
H: 0.44%
C: -0.23%
reach research market
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-21 (Crawled : 12:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -2.33%
H: 1.55%
C: 1.06%
UTHR | $237.06 1.11% 1.09% 610K
|
Health Technology
|
| O: 2.59%
H: 3.66%
C: -0.24%
year corporation therapeutics financial results
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2023 Financial Results Before the Market Opens on Wednesday, February 21, 2024
Published: 2024-02-14 (Crawled : 12:00) - biospace.com/
UTHR | $237.06 1.11% 1.09% 610K
|
Health Technology
|
| O: -0.29%
H: 0.72%
C: 0.61%
report year corporation therapeutics financial results market
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 0.48% 1.7M
|
Finance
|
22:30
NWFL | News | $24.6 2.03% 1.99% 9.9K
|
Finance
|
22:00
TGEN P 10000 | $0.685 39.71% 6.6K
|
Utilities
|
20:01
MNSB P 310 | $15.88 -2.93% -3.02% 46K
|
Finance
|
15:30
RMCF | $3.54 0.28% 7.1K
|
Consumer Non-Durables
|
20:10